AstraZeneca (AZN) – Globe Newswire
-
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
-
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
-
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
-
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in
-
Deutsche Bank’s Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
-
AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients
-
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022
-
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
-
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
-
AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022
-
AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022
-
EnWave Reports Fourth Quarter and Annual 2021 Consolidated Financial Results
-
Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China
-
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
-
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
-
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
-
EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration
-
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
-
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
-
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
-
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm
-
DEADLINE: Zhang Investor Law Alerts Investors of March 29 Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 9F, AstraZeneca, iRhythm Technologies, and Tyson Foods and Encourages Investors to Contact the Firm
-
FibroGen Provides Regulatory Update on Roxadustat
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bit Digital, CleanSpark, 9F, Inc., and AstraZeneca and Encourages Investors to Contact the Firm
-
AZN MARCH 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN
-
AZN DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AstraZeneca PLC– AZN
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 9F, AstraZeneca, iRhythm Technologies, and Tyson Foods and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: Lowey Dannenberg, P.C. Reminds Investors of Pending Securities Class Action Lawsuit against AstraZeneca plc and Encourages Investors to Inquire About the Lead Plaintiff Position Bef
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca and iRhythm Technologies and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: Lowey Dannenberg, P.C. Announces Filing of Securities Class Action Lawsuit Against AstraZeneca plc on Behalf of Investors Who Acquired Shares from May 21, 2020 to November 20, 2020
-
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
-
ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm
-
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
-
RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021
-
First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
-
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
-
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
-
Biopharma Leaders Unite to Stand with Science
-
RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease
-
RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights
-
Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
-
Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
-
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
-
Innate Pharma First Quarter 2020 Report
-
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
-
RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca
Back to AZN Stock Lookup
